Intranasal vaccination using dry powder vaccine formulation represents an attractive, non-invasive vaccination modality with better storage stability and added protection at the mucosal surfaces. Herein we report that it is feasible to induce specific mucosal and systemic antibody responses by intranasal immunization with a dry powder vaccine adjuvanted with an insoluble aluminum salt. The dry powder vaccine was prepared by thin-film freeze-drying of a model antigen, ovalbumin, adsorbed on aluminum (oxy)hydroxide as an adjuvant. Special emphasis was placed on the characterization of the dry powder vaccine formulation that can be realistically used in humans by a nasal dry powder delivery device. The vaccine powder was found to have "passable" to "good" flow properties, and the vaccine was uniformly distributed in the dry powder. An in vitro nasal deposition study using nasal casts of adult humans showed that around 90% of the powder was deposited in the nasal cavity. Intranasal immunization of rats with the dry powder vaccine elicited a specific serum antibody response as well as specific IgA responses in the nose and lung secretions of the rats. This study demonstrates the generation of systemic and mucosal immune responses by intranasal immunization using a dry powder vaccine adjuvanted with an aluminum salt.
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Intranasal vaccination using dry powder vaccine formulation represents an attractive, non-invasive vaccination modality with better storage stability and added protection at the mucosal surfaces. Herein we report that it is feasible to induce specific mucosal and systemic antibody responses by intranasal immunization with a dry powder vaccine adjuvanted with an insoluble aluminum salt. The dry powder vaccine was prepared by thin-film freeze-drying of a model antigen, ovalbumin, adsorbed on aluminum (oxy)hydroxide as an adjuvant. Special emphasis was placed on the characterization of the dry powder vaccine formulation that can be realistically used in humans by a nasal dry powder delivery device. The vaccine powder was found to have "passable" to "good" flow properties, and the vaccine was uniformly distributed in the dry powder. An in vitro nasal deposition study using nasal casts of adult humans showed that around 90% of the powder was deposited in the nasal cavity.
Intranasal immunization of rats with the dry powder vaccine elicited a specific serum antibody response as well as specific IgA responses in the nose and lung secretions of the rats. This study demonstrates the generation of systemic and mucosal immune responses by intranasal immunization using a dry powder vaccine adjuvanted with an aluminum salt.
Introduction
Adjuvants are needed for newer generation vaccines, such as protein subunit vaccines, to elicit strong immune responses [1] . Some insoluble aluminum salts, e.g. aluminum (oxy)hydroxide and aluminum (hydroxy)phosphate, are used in many currently licensed vaccines as adjuvants and possess excellent safety profiles [2, 3] . A major limitation of aluminum salt-adjuvanted vaccines is that they must be maintained in cold-chain (2-8°C) during transport and storage [4] . Accidentally subjecting the vaccines to slow freezing compromises their potency and/or efficacy. To overcome this issue, previously we reported that thin-film freeze-drying (TFFD) can be used to convert aluminum saltadjuvanted vaccine from a liquid dispersion to a dry powder without causing particle aggregation or decreasing immunogenicity following reconstitution [5, 6] . Importantly, the resultant dry powder vaccine is not sensitive to slow freezing and can be stored in temperatures as high as 40°C for up to 3 months [6] .
Aluminum salt-adjuvanted vaccines are generally administered by intramuscular, subcutaneous, or intradermal injection. However, reconstituting a dry powder vaccine before injection has various limitations such as the need for sterile water for injection, the need for trained medical personnel, and the increased chance of errors made when reconstituting the powder and filling syringes [7] . The nasal route for immunization offers some interesting opportunities. Almost all infectious agents enter the body through the mucosal surfaces [8] , and the nasal mucosa is often the first point of contact for inhaled pathogens. Therefore, ideally, to more effectively protect against inhaled pathogens, vaccines should be administered via the nasal mucosal surface to induce mucosal immunity to prevent infectious agents from entering the host [9] . Besides enabling vaccines to induce both mucosal and systemic immune responses [10, 11] , intranasal immunization has several other advantages as well. For example, the nasal mucosal surface is easily accessible and nasal immunization enables needle-free, non-invasive delivery of vaccines with the possibility of self-immunization.
Previously, it was thought that aluminum salt-based vaccine adjuvants are not capable of potentiating mucosal immune responses when given intranasally, and results from prior studies were ambiguous [12] [13] [14] [15] . However, data from our recent studies clearly showed that intranasal immunization with an antigen adsorbed on Alhydrogel ® induces significantly stronger antigen-specific immune responses, both systemically and in nasal and lung mucosal secretions, as compared to intranasal immunization with the antigen alone [16] . In the present study, we tested the feasibility of administering aluminum salt-adjuvanted dry powder vaccine prepared using our thin-film freeze-drying method directly via the nasal route to induce specific mucosal and systemic immune responses in a rat model. Others have administered dry powder vaccines intranasally in animal models [17, 18] , and even in clinical trials [19, 20] , however these vaccines do not contain aluminum salts as adjuvants [21] . Aluminum salt-adjuvanted dry powder vaccine preparations have also been administered in animal model(s) by a needle-free method, but by needle-free intradermal injection [22, 23] .
Materials and methods

Preparation of dry powder vaccine
The ovalbumin (OVA)-Alhydrogel ® dry powder vaccine was prepared as described previously [5, 6] . Briefly, OVA-Alhydrogel ® liquid vaccine was prepared by adding 10 mL of Alhydrogel ® (~10 mg/mL aluminum, manufactured by Brenntag, and supplied by InvivoGen, San Diego, CA) into a 50-mL tube followed by the addition of 10 mL of an OVA solution (1 mg/mL in 0.9% saline solution, w/v), and 200 mg of trehalose (Sigma-Aldrich, St. Louis, MO) to obtain a final formulation with 2% (w/v) of trehalose,~1% (w/v) of Alhydrogel ® , and 0.5 mg/mL of OVA. The vaccine suspension was converted into a dry powder using our previously reported thin-film freeze-drying method [5, 6] . The powder was dried using a VirTis AdVantage Bench Top Lyophilizer (The VirTis Company, Inc. Gardiner, NY). Lyophilization was performed over 72 h at pressures < 200 mTorr, while the shelf temperature was gradually ramped up from −40°C to 26°C. After lyophilization, the solid dry powder vaccine was transferred into a sealed container and stored in a desiccator at room temperature.
Physicochemical characterization
Particle size analysis
The geometric diameter of the dry powder vaccine was determined by low angle light scattering using a Malvern Spraytec ® (Malvern, UK)
outfitted with an inhalation cell and without an induction port. The nasal dry powder delivery device engineered in our laboratory (see Results and discussion section for details) was filled with the powder and then secured to the mouth of the induction port by a molded silicone adapter. The measurement was done at a flow rate of 25 L/min. Data acquisition took place over 4 s and only when laser transmission dropped below 95%.
Powder morphology and uniformity of distribution
Scanning electron microscopy (SEM) attached to energy-dispersive spectroscopy (EDS) was applied to understand the structure and morphology of the vaccine dry powder and to determine the uniformity of the distribution of the dry powder vaccine. A Hitachi S-5500 SEM (Hitachi High Technologies America, Inc., Pleasanton, CA) equipped with EDS was used at 10 kV accelerating voltage after sputter-coating the specimen with silver for 30 s in vacuum. Images at different magnifications were photographed from the SEM, and EDS plots showing elemental mapping were reported.
Flow properties
The tapped density of the dry powder vaccine was measured according to a method adapted from the United States Pharmacopeia (USP) < 616 > method I using a Varian Tapped Density Tester (Varian, Palo Alto, CA) [24] . An adaptation was made due to the limited supply of powder for testing, where a 100-mL graduated cylinder was replaced by a 5-mL graduated cylinder. Hausner ratio and Carr's compressibility index were calculated based on USP guidelines. Measurements of the static angle of repose of the dry powder vaccine were conducted as per USP < 1174 > [25] . Approximately 10 mL of powder was measured using a funnel and a flat collection surface.
Aerodynamic assessment of the dry powder vaccine
Aerodynamic assessment of the dry powder vaccine intended for nasal administration was performed in a nasal cast model [26] . The construction of the nasal casts from computed tomography (CT) scans has been detailed previously [26] . Five separate nasal casts were each made from a CT scan of a different adult individual [26] . The nasal casts can be divided into four sections representing the anterior region making up the vestibule (V) and nasal valve area; lower, middle and upper turbinates collectively called posterior nasal cavity (P); nasopharynx region (N); and the post-nasal fraction (F), which can either be collected in a cup if the model is operated without simulated inspiration airflow, or a removable filter is connected to the nasopharynx section if operated at a normal nasal breathing of 15 L/min. The cast was coated with 1% (v/v) Tween 20 in methanol and allowed to dry prior to deposition studies to minimize bias caused by particle bounce, similar to impaction studies performed on dry powder inhalers using cascade impactors [27, 28] . The dry powder formulation was administered to the cast with a nasal dry powder delivery device prepared in our own laboratory [29] (See Results and discussion section for details). The spray administration angle was set at 60°from horizontal, and the tip of the device was inserted at a distance of 5 mm. After administration, the cast was disassembled, and all parts were washed with 2% nitric acid carefully to collect the deposited fractions. Aluminum content was determined using a Varian 710-ES Inductively Coupled Plasma-Optical Emission Spectrometer (ICP-OES) in the Civil Architectural and Environmental Engineering Department at The University of Texas at Austin. The deposition profile is shown as % deposition recovered in different sections of the cast model and the post-nasal filter.
Animal study
The animal study was conducted following the U.S. National Research Council Guidelines for the Care and Use of Laboratory Animals. The Institutional Animal Care and Use Committee at The University of Texas at Austin approved the animal protocol. Female Sprague-Dowley rats, 6-8 weeks of age, were from Charles River Laboratories Inc. (Wilmington, MA). Rats were dosed intranasally on days 0, 14 and 28 with the OVA-Alhydrogel ® dry powder vaccine (IN Powder, n = 4) using the nasal dry powder delivery device engineered in our own lab. Rats were anesthetized and placed on their back at an angle of 45°. The exit diffuser of the device loaded with the vaccine powder was placed in the nostril of the anesthetized rat. The plunger of the syringe that contains 1 mL of air was depressed to create a powder plume of the vaccine in the nasal cavity. As controls, rats were also intranasally dosed with the OVA-Alhydrogel ® liquid vaccine (IN Liquid, n = 4), saline (n = 5), or subcutaneously (s.c.) injected with the OVAAlhydrogel ® liquid vaccine (SC Liquid, n = 4). For intranasal dosing of the liquid vaccine and normal saline, rats were placed on their back at an angle of 45°after anesthesia. The liquid vaccine or normal saline was administered using a fine pipette tip into the external nares with 10 μL volume in each nostril. The dose of OVA was 20 μg per rat, and 400 μg for Alhydrogel ® , in the IN Liquid and SC Liquid groups. In the IN Powder group, the dose of OVA in the first immunization was 21.6 ± 3.0 μg per rat. However, in the second and third immunizations, largely because the amount of dry powder vaccine that came out of the nasal dry powder delivery device varied each time, some rats were dosed twice, leading to an increase in the dose of OVA to more than 20 μg per rat (i.e. 49.4 ± 6.6 and 85.7 ± 19.5 μg per rat, respectively). Four weeks after the third dose, rats were euthanized to collect blood, nasal wash, and bronchoalveolar lavage (BAL). Nasal wash and BAL were collected as previously described by washing with 500 μL of sterile phosphate-buffered saline (PBS) [30] . The anti-OVA IgG and IgA levels in serum samples, nasal washes, and BAL samples were determined using enzyme-linked immunosorbent assay (ELISA) [31] . Briefly, EIA/RIA flat bottom, NUNC Maxisorp, 96-well plates (Thermo Fisher) were coated with 1 ng/μL of OVA solution in carbonate buffer (0.1 M, pH 9.0) overnight at 4°C. Plates were blocked with horse serum for one hour before adding the serum samples. Horse radish peroxidase (HRP)-labeled goat anti-rat immunoglobulin (IgG from Southern Biotech, Birmingham, AL; IgA from Life Technologies Corporation, Carlsbad, CA; 5000-fold dilution) was added into the plates, and the presence of bound antibody was detected in the presence of 3,3′,5,5′-tetramethylbenzidine solution (TMB, Sigma-Aldrich). The absorbance was read at 450 nm.
Rat brain tissues were collected upon euthanasia. The tissues were weighed, desiccated at 60°C for 12 h, and then incinerated with nitric acid (6.6 N) at 60°C for 15 h. Aluminum content was determined using an Agilent 7500ce quadruple Inductively Coupled Plasma attached with Mass Spectrometer (ICP-MS) in the Department of Geological Sciences at The University of Texas at Austin. ICP-MS has a detection limit of 1 ng/L (parts per trillion) for aluminum [32] . The aluminum levels are normalized to the dry weight of the brain tissues.
Noses of rats were prepared for histological examination. For this, the noses were separated, immobilized and decalcified. Afterwards the samples were sliced horizontally from the nostrils to the nasopharynx, and the slices were stained with hematoxylin and eosin (H&E) for evaluation under a microscope.
Statistics
Statistical analyses were completed by performing two-tailed Student's t-test for two-group analysis or one-way ANOVA followed by Tukey's post hoc analysis for multiple group comparisons using the GraphPad Prism 7 software (La Jolla, CA). A p value of ≤0.05 (two-tail) was considered significant.
Results and discussion
Although search for new vaccine adjuvants continues, insoluble aluminum salt-based adjuvants remain the preferred choice of adjuvants in vaccine formulations. Aluminum salt-adjuvanted vaccines, however, are particularly sensitive to unintentional slow freezing and/ or heat during transport and storage, and have to be maintained in coldchain (2-8°C). Unfortunately, breaching of the cold-chain is a common place, and not resource-limited [6] . To overcome this drawback, we previously reported that thin-film freeze-drying can be used to convert aluminum salt-adjuvanted vaccines from liquid to dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution [5] . The dry powder vaccine was stable in temperature ranging from 4°C to as high as 40°C for up to 3 months and was not sensitive to repeated freezing [6] . However, immunization using a hypodermic needle attached to a syringe filled with liquid vaccine that is reconstituted from the dry powder is not without limitations. Data from our recent study showed that it is feasible to administer a liquid dispersion of antigens adsorbed on an aluminum salt (i.e. Alhydrogel ® ) intranasally to induce specific systemic and mucosal immune responses [16] , prompting us to hypothesize that administering an aluminum-salt adjuvanted dry powder vaccine directly to the nose cavity will induce specific systemic and mucosal immune responses. We tested this hypothesis in a rat model with the dry powder of a vaccine prepared with OVA as a model antigen adsorbed on Alhydrogel ® , the international standard preparation of aluminum (oxy)hydroxide gel [33, 34] . OVA-Alhydrogel ® liquid vaccine was converted into a dry powder using our previously reported thin-film freeze-drying method with 2% of trehalose as a cryoprotectant. The dry powder does not contain any known mucoadhesive agent [21] .
Flow properties of the OVA-Alhydrogel ® dry powder vaccine
The flow properties measure the cohesive forces of a powder. In this study, the dry powder vaccine was prepared to explore the feasibility of intranasal administration, not their flow properties per se. However, the flow properties do affect the performance of the final product [35] . Also, because nasal delivery requires a fluidization of the powder bed, it is conceivable that the flow properties of the dry powder vaccine could affect the emitted dose from the nasal delivery device and the deposition of the vaccine in the nasal cavity.
The bulk and tapped densities of the dry powder was determined to be 0.040 ± 0.003 and 0.051 ± 0.007 g/mL, respectively ( Table 1) . The Hausner ratio and Carr's compressibility index of the dry powder vaccine were calculated to be 1.28 ± 0.07 and 21.80 ± 4.25, respectively, indicating that the flow property of the powder is "passable". The angle of repose of the dry powder was determined to be 25.94 ± 6.30°, which indicates a "good" flow property. The discrepancy in the flow property between the two methods of measurement could be explained by the low-density, porous and brittle particles of the thin-film freeze-dried vaccine powder, making a more compact cake when measuring the tapped density [36] .
Powder morphology and uniformity of distribution
SEM/EDS has an X-ray spectrometer attached to SEM, which allows elemental analysis in addition to SEM. SEM/EDS could be employed to determine the qualitative distribution of the OVA-Alhydrogel ® dry powder vaccine by taking advantage of the elemental aluminum in the formulation. This analysis gives an indication of how the OVAAlhydrogel ® vaccine is distributed in the dry powder. Shown in Fig. 1A are representative SEM images of the OVA-Alhydrogel ® dry powder vaccine. As expected, the OVA-Alhydrogel ® particles have a rough surface and irregular shape. Three random areas in an SEM graph of the vaccine dry powder (Fig. 1A and the left panel of Fig. 1B) were chosen for analysis, and four elements, Al, O, Na and Cl, were analyzed. SEM/ EDS showed the presence of all four elements analyzed (Fig. 1B-C) . The spectrum analysis and EDS map indicate a homogeneous distribution of the elements, implying that the vaccine was uniformly distributed in the dry powder.
Intranasal dry powder delivery device and characterization of dry powder delivered using the device
A nasal dry powder delivery device was developed in our lab for this study [29] . The device includes a housing reservoir (e.g. the squareshaped base of an oral gavage needle) and a pressurizing mechanism operable to pressurize gas/air chamber (e.g. similar to a syringe) to desired pressure [29] . The dry powder vaccine was loaded into the housing reservoir. Depressing the syringe plunger pushes air through the device, creating a powder plume that exits the orifice of the device 
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( Fig. 2A) . The particle size of the OVA-Alhydrogel ® dry powder vaccine delivered with the device was measured using a Malvern's Spraytec instrument and shown in Fig. 2B . The median diameter of the powder was 12.55 ± 4.69 μm.
Aerodynamic assessment of dry powder vaccine
The nasal cavity is the most easily accessible part of the respiratory system. It is worth noting that release of antigen from vaccine powder in the nasal cavity must take into account several factors, including wettability, dissolution rate, and the interaction of antigen-adjuvant with the mucus. However, for a nasal vaccine to afford protection, vaccines must present antigen to the target lymphoid tissues in nose. Nose-associated lymphoid tissue (NALT) in rodents refers to a pair of aggregated lymphoid tissues in the bottom of nasal ducts. However, in human nose cavity, the Waldeyer's ring, a well-known group of tonsils that includes the adenoid, tubal, palatine, and lingual tonsils, is the key lymphoid tissue [37] . A post mortem study by Debertin et al. (2003) provided evidence of the existence of NALT, in addition to the Walderyer's ring, in young children [38] . Pabst stated that there is not any reported data on the frequency of NALT in adolescents and adults [39] .
Evaluation of the nasal deposition of the dry powder vaccine would be beneficial in the development of nasal vaccines, because there are no guidelines or international consensus regarding the relationship between aerosol characteristics and deposition sites within the nasal cavities [40] . We used nasal casts based on the CT scans of five adult humans to predict the deposition of the dry powder vaccine after nasal administration. Fig. 3A shows the representative image of the different sections of the nasal casts used. The deposition study was carried out at 15 L/min of flow rate. As depicted in Fig. 3B, 62 .20 ± 8.14% the vaccine dry powder was recovered from the casts. Of the recovered powder, 64% was in the posterior nasal cavity. Overall, the nasal deposition can be deemed good, considering that out of the total powder recovered, about 90% stayed in the nose, and only around 10% of the powder was in the post-nasal fraction.
The immunogenicity of the dry powder vaccine after intranasal administration
To evaluate the feasibility of administering the OVA-Alhydrogel (Fig. 4A ) as well as OVA-specific IgA in rat nasal wash and BAL samples (Fig. 4B-C) . H&E staining of rat nasal cavities did not reveal any histological difference in the nasal mucosal tissues among rats that received the OVA-Alhydrogel ® dry powder intranasally, the OVA-Alhydrogel ® liquid vaccine intranasally or subcutaneously, or normal saline intranasally (data not shown), indicating that the OVAAlhydrogel ® dry powder vaccine was well tolerated locally when given intranasally.
The level of aluminum in the brain at the end of the study
Aluminum containing adjuvants possess an excellent safety profile [33, 41, 42] , and it was suggested that all the injected aluminum salts may be dissolved and absorbed eventually [43, 44] . Due to the large size of the particulates in the OVA-Alhydrogel ® vaccine dry powder and the OVA-Alhydrogel ® liquid vaccine (i.e. X 50 of~12 μm and 8 μm, respectively), the OVA-Alhydrogel ® particles are expected to largely stay in the nasal cavity after nasal administration [45, 46] . However, there is a potential of brain exposure of aluminum via the olfactory epithelium [47] [48] [49] . In some previous studies, no significant brain aluminum levels were seen in rats after 4 weeks of continuous exposure of insoluble aluminum (oxy)hydroxide [48] , but others showed elevated brain levels of aluminum in rabbits after one month of continuous nasal exposure of soluble aluminum salts in a solution (e.g. aluminum lactate or aluminum chloride, as 'Gelfoam') [49] . Therefore, we measured aluminum levels in the brain tissues of the immunized rats upon euthanasia (i.e. four weeks after the last immunization). Fig. 5 shows the levels of aluminum determined in rat brain tissues. There was not any significant difference in aluminum levels among all four groups, suggesting that intranasal administration of the OVA-Alhydrogel ® vaccine dry powder, even at higher doses, may not increase the level of aluminum in the brain as compared to subcutaneous injection of the OVAAlhydrogel ® liquid vaccine. For rodents, about 50% of the nasal cavity 
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is lined with olfactory epithelium, compared to 3% for humans [50] , which will likely further limit nose to brain transport of aluminum in humans, if any. Only a systemic comparison of the aluminum levels in brain tissues at different time points after the vaccine is given intranasally as a dry powder or subcutaneously or intramuscularly as a liquid dispersion at exactly the same dose will allow us to understand whether intranasal administration of the vaccine dry powder will affect its level in the brain. Nonetheless, it is unlikely that the transient nasal exposure of the insoluble aluminum salt in a dry powder vaccine for 1-3 times at a relatively low dose would lead to a significantly elevated level of aluminum in the brain, as compared to when the same dose of insoluble aluminum salt-adjuvanted vaccine is given by the traditional intramuscular injection.
As mentioned earlier, we have shown that our dry powder vaccine can overcome the stability issue of liquid aluminum salt-adjuvanted vaccines (i.e. sensitive to heat and slow freezing) [6] . There have been a few reported studies investigating intranasal delivery of dry powder vaccines [17] [18] [19] [20] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . However, to our best knowledge, the present study represents the first study testing the feasibility of intranasal immunization with an aluminum salt-adjuvanted dry powder vaccine. Existing human nasal vaccines (e.g., FluMist ® , Nasovac ® ) are live attenuated vaccines [66] . Subunit vaccines provide more challenges for nasal immunization, in part due to the low immunogenicity of subunit protein antigens, as compared to live attenuated vaccines [67] . Therefore, the availability of proper adjuvant(s) plays a critical role for successful nasal mucosal immunization. For decades, scientists have been searching for a safe and effective nasal mucosal vaccine adjuvant, with only limited success. Our data showed that the aluminum salts in existing injectable human vaccines may be used as nasal mucosal vaccine adjuvants [16] . Administering aluminum salt-adjuvanted vaccine powder intranasally can potentially address the cold-chain requirement associated with aluminum salt-adjuvanted liquid vaccines as well as the limitations associated with filling liquid vaccines reconstituted from dry powder into syringes for hypodermic needle-based injection.
Conclusion
In conclusion, we presented data demonstrating the feasibility of intranasally administering a dry powder vaccine adjuvanted with an aluminum salt to induce specific mucosal and systemic immune responses in a rat model, although the doses of the antigen for the dry powder vaccine were 2.3-and 3.9-fold higher than those for the liquid vaccine in the second and third immunizations, respectively. Further studies using comparable doses are required to fully assess and compare the immunogenicity of the dry powder and liquid vaccines. 
